摘要
达格列净是一种新型降糖药,通过抑制近端肾小管钠-葡萄糖协同转运蛋白2介导的葡萄糖重吸收,促进尿糖排泄而发挥降糖作用。临床上可单药或者与其他降糖药联用治疗2型糖尿病,疗效显著,安全性高。本文对达格列净的降糖机制、临床应用、安全性等进行综述,为其临床合理应用及降糖药研发提供参考。
Dapagliflozin is a novel hypoglycemic agent that exerts hypoglycemic effects by inhibiting proximal tubular sodium-glucose cotransporter 2-mediated glucose reabsorption and promoting urinary glucose excretion.It can be used alone or in combination with other hypoglycemic agents for the treatment of type 2 diabetes,with significant efficacy and high safety in clinic practice..In this paper,the hypoglycemic mechanism,clinical application and safety of dapagliflozin were reviewed to provide reference for its rational clinical application and research and development of hypoglycemic agents.
作者
刘玉萍
刘烨
邱小玉
马国
LIU Yu-ping;LIU Ye;QIU Xiao-yu;MA Guo(School of Pharmacy,Fudan University,Shanghai 201203,China)
出处
《中国医院药学杂志》
CAS
北大核心
2019年第18期1896-1899,共4页
Chinese Journal of Hospital Pharmacy
基金
国家自然科学基金面上项目(编号:81374051,81873087)
上海市卫生和计划生育委员会科研课题(编号:201740094,2018YP001)
复旦大学附属闵行医院-复旦大学药学院战略合作融合基金(编号:RO-MY201707)资助
